IDH mutation impairs histone demethylation and results in a block to cell differentiation
- PMID: 22343901
- PMCID: PMC3478770
- DOI: 10.1038/nature10860
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Abstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Conflict of interest statement
The authors declare competing financial interests: details accompany the full-text HTML version of the paper at
Figures
Comment in
-
Metabolism: unmasking an oncometabolite.Nat Rev Cancer. 2012 Mar 1;12(4):229. doi: 10.1038/nrc3248. Nat Rev Cancer. 2012. PMID: 22378191 No abstract available.
Similar articles
-
2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation.Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12851-12856. doi: 10.1073/pnas.1817662116. Epub 2019 Jun 10. Proc Natl Acad Sci U S A. 2019. PMID: 31182575 Free PMC article.
-
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.Cancer Discov. 2023 Jun 2;13(6):1478-1497. doi: 10.1158/2159-8290.CD-22-0825. Cancer Discov. 2023. PMID: 36847506 Free PMC article.
-
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11. Chin Clin Oncol. 2017. PMID: 28705010
-
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.Clin Cancer Res. 2021 Jan 15;27(2):383-388. doi: 10.1158/1078-0432.CCR-20-1827. Epub 2020 Sep 3. Clin Cancer Res. 2021. PMID: 32883741 Review.
-
Targeting isocitrate dehydrogenase (IDH) in cancer.Discov Med. 2016 May;21(117):373-80. Discov Med. 2016. PMID: 27355333 Review.
Cited by
-
Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers.J Clin Med. 2022 Nov 16;11(22):6787. doi: 10.3390/jcm11226787. J Clin Med. 2022. PMID: 36431263 Free PMC article. Review.
-
The Significance of Mitochondrial Dysfunction in Cancer.Int J Mol Sci. 2020 Aug 5;21(16):5598. doi: 10.3390/ijms21165598. Int J Mol Sci. 2020. PMID: 32764295 Free PMC article. Review.
-
Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?Carcinogenesis. 2015 Jun;36 Suppl 1(Suppl 1):S203-31. doi: 10.1093/carcin/bgv037. Carcinogenesis. 2015. PMID: 26106140 Free PMC article. Review.
-
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Genes Dev. 2013 Apr 15;27(8):836-52. doi: 10.1101/gad.217406.113. Genes Dev. 2013. PMID: 23630074 Free PMC article. Review.
-
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30. Cancer Res. 2013. PMID: 23204232 Free PMC article.
References
-
- Amary MF, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–343. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
